Literature DB >> 26367466

Cytotoxicity of HBD3 for dendritic cells, normal human epidermal keratinocytes, hTERT keratinocytes, and primary oral gingival epithelial keratinocytes in cell culture conditions.

Nattawut Leelakanok1, Carol L Fischer2, Amber M Bates3, Janet M Guthmiller4, Georgia K Johnson5, Aliasger K Salem6, Kim A Brogden7, Nicole K Brogden8.   

Abstract

Human β-defensin 3 (HBD3) is a prominent host defense peptide. In our recent work, we observed that HBD3 modulates pro-inflammatory agonist-induced chemokine and cytokine responses in human myeloid dendritic cells (DCs), often at 20.0 μM concentrations. Since HBD3 can be cytotoxic in some circumstances, it is necessary to assess its cytotoxicity for DCs, normal human epidermal keratinocytes (NHEKs), human telomerase reverse transcriptase (hTERT) keratinocytes, and primary oral gingival epithelial (GE) keratinocytes in different cell culture conditions. Cells, in serum free media with resazurin and in complete media with 10% fetal bovine serum and resazurin, were incubated with 5, 10, 20, and 40 μM HBD3. Cytotoxicity was determined by measuring metabolic conversion of resazurin to resorufin. The lethal dose 50 (LD50, mean μM±Std Err) values were determined from the median fluorescent intensities of test concentrations compared to live and killed cell controls. The LD50 value range of HBD3 was 18.2-35.9 μM in serum-free media for DCs, NHEKs, hTERT keratinocytes, and GE keratinocytes, and >40.0 μM in complete media. Thus, HBD3 was cytotoxic at higher concentrations, which must be considered in future studies of HBD3-modulated chemokine and cytokine responses in vitro.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cytotoxicity; Defensins; Dendritic cells; Epidermal Keratinocytes; Gingival epithelial GE keratinocytes; HBD3; hTERT Keratinocytes

Mesh:

Substances:

Year:  2015        PMID: 26367466      PMCID: PMC4600674          DOI: 10.1016/j.toxlet.2015.09.006

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  42 in total

1.  Lipid-specific membrane activity of human beta-defensin-3.

Authors:  Arne Böhling; Sven O Hagge; Stefanie Roes; Rainer Podschun; Hany Sahly; Jürgen Harder; Jens-Michael Schröder; Joachim Grötzinger; Ulrich Seydel; Thomas Gutsmann
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

2.  Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines.

Authors:  François Niyonsaba; Hiroko Ushio; Nobuhiro Nakano; William Ng; Koji Sayama; Koji Hashimoto; Isao Nagaoka; Ko Okumura; Hideoki Ogawa
Journal:  J Invest Dermatol       Date:  2006-10-19       Impact factor: 8.551

3.  Inhibition of activation of the classical pathway of complement by human neutrophil defensins.

Authors:  R H van den Berg; M C Faber-Krol; S van Wetering; P S Hiemstra; M R Daha
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

4.  Differential cytotoxicity of long-chain bases for human oral gingival epithelial keratinocytes, oral fibroblasts, and dendritic cells.

Authors:  Christopher Poulsen; Leslie A Mehalick; Carol L Fischer; Emily A Lanzel; Amber M Bates; Katherine S Walters; Joseph E Cavanaugh; Janet M Guthmiller; Georgia K Johnson; Philip W Wertz; Kim A Brogden
Journal:  Toxicol Lett       Date:  2015-05-21       Impact factor: 4.372

5.  The structural parameters for antimicrobial activity, human epithelial cell cytotoxicity and killing mechanism of synthetic monomer and dimer analogues derived from hBD3 C-terminal region.

Authors:  L Zhou; S P Liu; L Y Chen; J Li; L B Ong; L Guo; T Wohland; C C Tang; R Lakshminarayanan; J Mavinahalli; C Verma; R W Beuerman
Journal:  Amino Acids       Date:  2010-04-17       Impact factor: 3.520

6.  Identification of hBD-3 in respiratory tract and serum: the increase in pneumonia.

Authors:  H Ishimoto; H Mukae; Y Date; T Shimbara; M S Mondal; J Ashitani; T Hiratsuka; S Kubo; S Kohno; M Nakazato
Journal:  Eur Respir J       Date:  2006-02       Impact factor: 16.671

7.  Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic.

Authors:  J Harder; J Bartels; E Christophers; J M Schroder
Journal:  J Biol Chem       Date:  2000-11-20       Impact factor: 5.157

8.  Expression of human beta-defensins in children with chronic inflammatory bowel disease.

Authors:  Matthias Zilbauer; Andreas Jenke; Gundula Wenzel; Jan Postberg; Andreas Heusch; Alan D Phillips; Gabriele Noble-Jamieson; Franco Torrente; Camilla Salvestrini; Robert Heuschkel; Stefan Wirth
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

9.  Linear analogues of human beta-defensin 3: concepts for design of antimicrobial peptides with reduced cytotoxicity to mammalian cells.

Authors:  Shouping Liu; Lei Zhou; Jing Li; Anita Suresh; Chandra Verma; Yong Hwee Foo; Eric P H Yap; Donald T H Tan; Roger W Beuerman
Journal:  Chembiochem       Date:  2008-04-14       Impact factor: 3.164

10.  Membrane damage and repair in primary monocytes exposed to human β-defensin-3.

Authors:  Anthony B Lioi; Angel L Reyes Rodriguez; Nicholas T Funderburg; Zhimin Feng; Aaron Weinberg; Scott F Sieg
Journal:  J Leukoc Biol       Date:  2012-07-26       Impact factor: 4.962

View more
  3 in total

1.  Human beta defensin 3 alters matrix metalloproteinase production in human dendritic cells exposed to Porphyromonas gingivalis hemagglutinin B.

Authors:  Monica Raina; Amber M Bates; Carol L Fischer; Ann Progulske-Fox; Taher Abbasi; Shireen Vali; Kim A Brogden
Journal:  J Periodontol       Date:  2018-03       Impact factor: 6.993

Review 2.  The Dichotomous Responses Driven by β-Defensins.

Authors:  Jennifer R Shelley; Donald J Davidson; Julia R Dorin
Journal:  Front Immunol       Date:  2020-06-12       Impact factor: 7.561

3.  Human β-Defensin 2 Mediated Immune Modulation as Treatment for Experimental Colitis.

Authors:  Louis Koeninger; Nicole S Armbruster; Karoline Sidelmann Brinch; Søren Kjaerulf; Birgitte Andersen; Carolin Langnau; Stella E Autenrieth; Dominik Schneidawind; Eduard F Stange; Nisar P Malek; Peter Nordkild; Benjamin A H Jensen; Jan Wehkamp
Journal:  Front Immunol       Date:  2020-01-31       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.